Split-dose or hybrid nonsteroidal anti-inflammatory drugs and Nacetylcysteine therapy for prevention of post-retrograde cholangiopancreatography pancreatitis

被引:0
作者
Laura Pavel [1 ]
Gheorghe Gh B?lan
Alexandra Nicorescu [2 ]
Georgiana Emmanuela G?lc?-Blanariu
C?t?lin Sfarti
?tefan Chiriac
Smaranda Diaconescu [3 ]
Vasile Liviu Drug [1 ]
Gheorghe B?lan
Gabriela ?tef?nescu
机构
[1] Gastroenterology, “Grigore T.Popa” University of Medicine and Pharmacy
[2] Endocrinology, “Grigore T. Popa” University of Medicine and Pharmacy
[3] Department of Mother and Child Medicine, “Grigore T. Popa” University of Medicine and Pharmacy
关键词
Endoscopic retrograde cholangiopancreatography; Prophylaxis; Postendoscopic retrograde cholangiopancreatography pancreatitis; Nonsteroidal antiinflammatory drugs; N-acetylcysteine;
D O I
暂无
中图分类号
R575.6 [胆囊疾病]; R576 [胰腺疾病];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Despite significant technical and training improvements, the incidence of postendoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) has not significantly dropped. Although many studies have evaluated the efficacy of various agents, e.g. nonsteroidal anti-inflammatory drugs, octreotide,antioxidants, administered via various dosages, routes(oral, intrarectal or parenteral), and schedules(before or after the procedure), the results have been conflicting.AIM To evaluate efficacy of three pharmacologic prophylactic methods for prevention of PEP.METHODS In this prospective, single-center randomized trial, patients who underwent firsttime ERCP for choledocholithiasis were randomly assigned to three groups. The first group received 600 mg N-acetylcysteine 15 min prior to ERCP, and perrectum administration of 50 mg indomethacin both prior to and after completion of the ERCP. The second group was administered only the 50 mg indomethacin per-rectum both prior to and after the ERCP. The third group was administeredper-rectum 100 mg indomethacin only after the ERCP, representing the control group given the guideline-recommended regimen. The primary end-point was PEP prevention.RESULTS Among the total 211 patients evaluated during the study, 186 fulfilled the inclusion criteria and completed the protocol. The percentages of patients who developed PEP in each of the three groups were not significantly different(χ2 =2.793, P = 0.247). Among the acute PEP cases, for all groups, 14 patients developed mild pancreatitis(77.77%) and 4 moderate. No severe cases of PEP occurred, and in all PEP cases the resolution was favorable. No adverse events related to the medications(digestive hemorrhage, rectal irritation, or allergies)occurred.CONCLUSION The efficacies of split-dose indomethacin and combined administration(Nacetylcysteine with indomethacin) for preventing PEP were similar to that of the standard regimen.
引用
收藏
页码:300 / 310
页数:11
相关论文
共 50 条
  • [31] Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis
    Akshintala, Venkata S.
    Weiland, Christina J. Sperna
    Bhullar, Furqan A.
    Kamal, Ayesha
    Kanthasamy, Kavin
    Kuo, Albert
    Tomasetti, Cristian
    Gurakar, Merve
    Drenth, Joost P. H.
    Yadav, Dhiraj
    Elmunzer, B. Joseph
    Reddy, D. Nageshwar
    Goenka, Mahesh K.
    Kochhar, Rakesh
    Kalloo, Anthony N.
    Khashab, Mouen A.
    Van Geenen, Erwin J. M.
    Singh, Vikesh K.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (09): : 733 - 742
  • [32] Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs
    Jürgen Steinmeyer
    Arthritis Research & Therapy, 2
  • [33] Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs
    Steinmeyer, J
    ARTHRITIS RESEARCH, 2000, 2 (05) : 379 - 385
  • [34] The prevention of gastropathy and upper abdominal symptoms caused by nonsteroidal anti-inflammatory drugs
    Vakil, Nimish
    REVIEWS IN GASTROENTEROLOGICAL DISORDERS, 2006, 6 (04) : 221 - 226
  • [35] Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis
    Leerhoy, Bonna
    Nordholm-Carstensen, Andreas
    Novovic, Srdan
    Hansen, Mark Berner
    Jorgensen, Lars Nannestad
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (08) : 1007 - 1012
  • [36] Rectal nonsteroidal anti-inflammatory drugs administration is effective for the prevention of post-ERCP pancreatitis: An updated meta-analysis of randomized controlled trials
    Yang, Chong
    Zhao, Yanting
    Li, Wentao
    Zhu, Shikai
    Yang, Hongji
    Zhang, Yu
    Liu, Xi
    Peng, Nan
    Fan, Ping
    Jin, Xin
    PANCREATOLOGY, 2017, 17 (05) : 681 - 688
  • [37] Nonsteroidal anti-inflammatory drugs before endoscopic ultrasound guided tissue acquisition to reduce the incidence of post procedural pancreatitis
    de Jong, Mike
    van Delft, Foke
    Roozen, Christine
    van Geenen, Erwin-Jan
    Bisseling, Tanya
    Siersema, Peter
    Bruno, Marco
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (08) : 811 - 816
  • [38] Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: A systematic review
    Asano, TK
    McLeod, RS
    DISEASES OF THE COLON & RECTUM, 2004, 47 (05) : 665 - 673
  • [39] The Effectiveness of the Rectal Administration of Low-dose Diclofenac for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis
    Okuno, Mitsuru
    Shiroko, Junko
    Taguchi, Daisuke
    Yamaguchi, Kimihiro
    Takada, Jun
    Imai, Susumu
    Sato, Hiroyuki
    Thanabashi, Shinobu
    INTERNAL MEDICINE, 2018, 57 (16) : 2289 - 2294
  • [40] Continuing war on pain: a personalized approach to the therapy with nonsteroidal anti-inflammatory drugs and opioids
    Bach-Rojecky, Lidija
    Vadunec, Dalia
    Zunic, Katarina
    Kurija, Jelena
    Sipicki, Sara
    Gregg, Ryan
    Mikula, Ivan
    Primorac, Dragan
    PERSONALIZED MEDICINE, 2019, 16 (02) : 171 - 184